Newland Pharmaceutical Co., Ltd. (SHE:301277)
China
· Delayed Price · Currency is CNY 11.53
0.00 (0.00%)
Apr 29, 2026, 4:00 PM EDT
Newland Pharmaceutical Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2018 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | 2021 - 2019 |
| Operating Revenue | 649.97 | 662.81 | 720.99 | 643.85 | 621.21 | 508.93 | Upgrade
|
| Other Revenue | 9.57 | 9.57 | 5.44 | 7.59 | 6.15 | 4.91 | Upgrade
|
| Revenue | 659.54 | 672.38 | 726.44 | 651.44 | 627.36 | 513.84 | Upgrade
|
| Revenue Growth (YoY) | -13.41% | -7.44% | 11.51% | 3.84% | 22.09% | 18.63% | Upgrade
|
| Cost of Revenue | 455.75 | 447.24 | 437.43 | 392.84 | 404.01 | 307.82 | Upgrade
|
| Gross Profit | 203.79 | 225.14 | 289 | 258.6 | 223.36 | 206.02 | Upgrade
|
| Selling, General & Admin | 59.22 | 55.91 | 47.62 | 44.49 | 38.83 | 31.56 | Upgrade
|
| Research & Development | 40.17 | 46.18 | 55.49 | 51.96 | 30 | 20.59 | Upgrade
|
| Other Operating Expenses | 6.2 | 4.43 | 2.71 | 3.89 | 6.99 | 6.4 | Upgrade
|
| Operating Expenses | 104.4 | 105.66 | 108.1 | 96.75 | 78.04 | 69.69 | Upgrade
|
| Operating Income | 99.39 | 119.49 | 180.91 | 161.85 | 145.31 | 136.33 | Upgrade
|
| Interest Expense | -0.11 | -0.21 | -0.09 | -0.13 | -6.88 | -6.71 | Upgrade
|
| Interest & Investment Income | 8.83 | 10.94 | 16.7 | 19.63 | 1.34 | 0.26 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.03 | -0.03 | 0.25 | 0.06 | 0.29 | -0.13 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.19 | -0.02 | -0.06 | -0.12 | -0.09 | -0.06 | Upgrade
|
| EBT Excluding Unusual Items | 108.25 | 130.16 | 197.7 | 181.29 | 139.97 | 129.69 | Upgrade
|
| Gain (Loss) on Sale of Investments | 1.42 | 0.19 | -0.23 | 0.04 | 1.36 | 0.17 | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.33 | - | - | 0.07 | -0.44 | -0.21 | Upgrade
|
| Asset Writedown | -4.18 | -1.49 | -2.62 | -1.46 | -0.32 | -0.11 | Upgrade
|
| Other Unusual Items | 5.26 | 5.26 | 2.5 | 1.22 | 2.31 | 2.4 | Upgrade
|
| Pretax Income | 111.08 | 134.12 | 197.35 | 181.16 | 142.88 | 131.94 | Upgrade
|
| Income Tax Expense | 11.76 | 14.06 | 24.34 | 23.96 | 11.17 | 17.11 | Upgrade
|
| Earnings From Continuing Operations | 99.32 | 120.07 | 173.01 | 157.2 | 131.71 | 114.82 | Upgrade
|
| Minority Interest in Earnings | 1.45 | 1.18 | 0.62 | 1.78 | 0.6 | 0.15 | Upgrade
|
| Net Income | 100.78 | 121.25 | 173.63 | 158.98 | 132.3 | 114.98 | Upgrade
|
| Net Income to Common | 100.78 | 121.25 | 173.63 | 158.98 | 132.3 | 114.98 | Upgrade
|
| Net Income Growth | -42.18% | -30.17% | 9.21% | 20.16% | 15.07% | -2.94% | Upgrade
|
| Shares Outstanding (Basic) | 391 | 391 | 395 | 391 | 302 | 294 | Upgrade
|
| Shares Outstanding (Diluted) | 391 | 391 | 395 | 391 | 302 | 294 | Upgrade
|
| Shares Change (YoY) | -0.94% | -0.88% | 1.05% | 29.52% | 2.59% | 0.64% | Upgrade
|
| EPS (Basic) | 0.26 | 0.31 | 0.44 | 0.41 | 0.44 | 0.39 | Upgrade
|
| EPS (Diluted) | 0.26 | 0.31 | 0.44 | 0.41 | 0.44 | 0.39 | Upgrade
|
| EPS Growth | -41.63% | -29.54% | 8.08% | -7.22% | 12.17% | -3.36% | Upgrade
|
| Free Cash Flow | -2.85 | 15.55 | 15.97 | 162.94 | 8.5 | 23.68 | Upgrade
|
| Free Cash Flow Per Share | -0.01 | 0.04 | 0.04 | 0.42 | 0.03 | 0.08 | Upgrade
|
| Dividend Per Share | 0.200 | 0.200 | 0.400 | 0.204 | 0.170 | - | Upgrade
|
| Dividend Growth | -50.00% | -50.00% | 95.98% | 19.99% | - | - | Upgrade
|
| Gross Margin | 30.90% | 33.48% | 39.78% | 39.70% | 35.60% | 40.09% | Upgrade
|
| Operating Margin | 15.07% | 17.77% | 24.90% | 24.85% | 23.16% | 26.53% | Upgrade
|
| Profit Margin | 15.28% | 18.03% | 23.90% | 24.40% | 21.09% | 22.38% | Upgrade
|
| Free Cash Flow Margin | -0.43% | 2.31% | 2.20% | 25.01% | 1.35% | 4.61% | Upgrade
|
| EBITDA | 156.25 | 172.06 | 216.31 | 190.69 | 167.38 | 157.19 | Upgrade
|
| EBITDA Margin | 23.69% | 25.59% | 29.78% | 29.27% | 26.68% | 30.59% | Upgrade
|
| D&A For EBITDA | 56.86 | 52.57 | 35.4 | 28.84 | 22.06 | 20.86 | Upgrade
|
| EBIT | 99.39 | 119.49 | 180.91 | 161.85 | 145.31 | 136.33 | Upgrade
|
| EBIT Margin | 15.07% | 17.77% | 24.90% | 24.85% | 23.16% | 26.53% | Upgrade
|
| Effective Tax Rate | 10.59% | 10.48% | 12.33% | 13.23% | 7.82% | 12.97% | Upgrade
|
| Revenue as Reported | 659.54 | 672.38 | 726.44 | 651.44 | 627.36 | 513.84 | Upgrade
|
| Advertising Expenses | - | 1.1 | 0.85 | 0.51 | 0.2 | 0.28 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.